Published in Law and Health Weekly, October 1st, 2005
"We are very pleased with this decision," said Apotex CEO Dr. Barry Sherman. "This confirms what we believed all along: Our generic version of Neurontin does not infringe Pfizer's patent and deserves to be on the market," Sherman commented.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law and Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.